Does low LH with low free and bioavailable testosterone indicate reduced central HPG-axis signaling?

In male reproductive endocrinology, the hypothalamic-pituitary-gonadal (HPG) axis relies on precise feedback loops to maintain systemic androgen levels.

Clinical implications and diagnostic utility

• Central axis impairment: Low luteinizing hormone (LH) in the presence of low free and bioavailable testosterone clinically defines secondary (hypogonadotropic) hypogonadism. Under normal physiological conditions, decreased testosterone triggers a compensatory central increase in gonadotropin-releasing hormone (GnRH) and subsequent pituitary LH secretion.
• Failure of feedback: Low or "inappropriately normal" LH levels in a low-testosterone state indicate a failure of this central feedback loop, distinguishing secondary hypogonadism from primary testicular failure.
• Fractionation value: Measuring free and bioavailable testosterone fractions is highly valuable, particularly when sex hormone-binding globulin (SHBG) is altered by metabolic status, to accurately confirm central HPG-axis suppression.

Molecular mechanisms of steroidogenesis

• Receptor activation: Pituitary LH acts as the primary endocrine trigger for Leydig-cell steroidogenesis by binding to its G-protein coupled receptor on the Leydig cell membrane.
• Intracellular signaling: This binding activates a Gs-coupled signaling cascade that stimulates adenylate cyclase, raising intracellular cyclic AMP (cAMP) and activating protein kinase A (PKA).
• Rate-limiting transport: The cAMP-PKA pathway rapidly induces and phosphorylates the Steroidogenic Acute Regulatory (StAR) protein. StAR mediates the rate-limiting step of steroidogenesis by transporting free cholesterol across the aqueous intermembrane space to the inner mitochondrial membrane, where enzymes convert it stepwise into testosterone.

Bottom line

• Low LH combined with suppressed free and bioavailable testosterone is a clear diagnostic hallmark of central HPG-axis impairment, arising from a failure to initiate the LH-cAMP-PKA pathway and StAR-mediated mitochondrial cholesterol transport required for Leydig-cell testosterone synthesis.